You are here: Home » Markets » News
Business Standard

Dr Reddy's Labs loses over Rs 10,000-cr mcap; stock tanks 15%

USFDA issued warning letter relating to its two API manufacturing facilities in Andhra Pradesh and Telangana.

SI Reporter  |  Mumbai 

Dr Reddy's Laboratories loses over Rs 10,000 crore mcap; stock tanks 15%

Dr Reddy’s Laboratories lost more than Rs 10,000 crore market capitalisation as stock recorded its biggest single day fall in past one decade, after the drug maker said that it has received a warning letter issued by the US drug regulator relating to its two active pharmaceutical ingredients (API) manufacturing facilities in Andhra Pradesh and Telangana.

The stock plunged 15%, its second biggest single-day fall, to settle at Rs 3,630, which wiped out Rs 10,628 crore in market capitalisation (mcap) on Friday. At close of trade, the company’s mcap stood at Rs 61,916 crore against Rs 72,544 crore on Thursday, BSE data show. In March 1, 2004, the stock had tumbled 18% in a single day.

Dr Reddy's Laboratories said that it has received a warning letter issued by the United States Food and Drug Administration (USFDA) dated 5 November 2015 relating to the company's API manufacturing facilities at Srikakulam in Andhra Pradesh and Miryalaguda in Telangana, as well as oncology formulation manufacturing facility at Duvvada in Visakhapatnam, Andhra Pradesh.

The management will continue to actively engage with the USFDA to resolve these issues and the management have also embarked on an initiative to revamp the company's quality systems and processes, as an organization-wide priority, Dr Reddy's CEO G V Prasad stated.

Sarabjit Kour Nangra, VP Research - Pharma, Angel Broking, in a client report said that the impact of the API facilities would be depend upon how quick the company fixes the USFDA issues plant transfers or does third party sources. Nonetheless, the near term performance of the company will be impacted and maintains a neutral rating on the stock.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, November 06 2015. 15:55 IST
RECOMMENDED FOR YOU
.